Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Archive

Hadassah Medical Center Appoints New Director of Pediatric Intensive Care

Dr. Philip Toltzis

Dr. Philip Toltzis, Interim Chief of the Division of Pharmacology and Critical Care at Rainbow Babies and Children's Hospital, a teaching hospital of Case Western Reserve University in Cleveland, Ohio, has been appointed Director of Pediatric Intensive Care. He succeeds the late Dr. Ido Yatziv and Acting Director Dr. Jacques Braun.

While in Cleveland, Dr. Toltzis also served as Professor of Pediatrics at Case Western Reserve University School of Medicine. A graduate of the University of Michigan, Phi Beta Kappa, and the University of Pennsylvania Perelman School of Medicine, Dr. Toltzis simultaneously served as a Clinical Fellow in the Division of Infectious Diseases at Children's Hospital in Boston, Massachusetts and as a Research Fellow in Infectious Diseases at Harvard Medical School in Boston. He subsequently served as a Clinical and Research Fellow in the Division of Pharmacology and Critical Care at Rainbow Babies and Children's Hospital.

As a leader in his field, Dr. Toltzis has been invited to sit on a variety of national committees in the United States. Most recently, he was a member of the Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Working Group on Ventilator-Associated Events.

Dr. Toltzis comes to Hadassah with an extensive research resume, as well as academic and clinical accomplishments which have garnered him numerous awards, honors, and grants. A member of the editorial board of the Journal of Pediatrics, he has authored and co-authored more than 70 articles that have been published in prestigious medical journals as well as chapters in more than 20 textbooks.

Click here for more news from Hadassah Medical Organization>>

Date: 1/9/2013

More hMedicine Stories

Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America